Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2020. február 17., hétfő 10:00 |
A new expert consensus publication provides practical guidance on the use of omega-3 fatty acids in parenteral nutrition |
|
Bad Homburg, Germany, 17 February, 2020 (APA/OTS) - Fresenius Kabi, a global leader in clinical nutrition, announces that the Journal of Parenteral and Enteral Nutrition (JPEN) has recently published "Lipids in Parenteral Nutrition: Translating Guidelines into Clinical Practice".(1) The publication represents the largest set of expert consensus statements to provide guidance on the use of fish oil-containing lipid emulsions in clinical practice. |
An international panel of leading experts in clinical nutrition,
lipid metabolism, and pharmacology developed a set of 43 consensus
recommendations. The recommendations aim to help healthcare
professionals to navigate issues around prescription,
administration, safety, and monitoring of lipids - from short- to
long-term parenteral nutrition, from pediatric to adult patients,
from home to hospital care.
Fish oil-containing parenteral nutrition has been shown to have a
variety of beneficial effects on key biological functions, including
modulation of the immune and inflammatory response. A growing body
of evidence suggests that these properties improve clinical
outcomes, e.g. infection rates, sepsis rate, length of ICU and
hospital stay.(2)
Current guidelines of international clinical societies recommend
the use of fish oil-containing lipid emulsions in parenteral
nutrition.(3-5) Regarding specific nutrients, only parenteral lipid
emulsions with EPA + DHA* are recommended by the European Society
for Clinical Nutrition and Metabolism (ESPEN) guideline on clinical
nutrition in the intensive care unit.(4)
To read the summary of consensus statements along with the review
of current evidence on the clinical benefits of omega-3 fatty acids
in parenteral nutrition across the healthcare continuum, visit
https://onlinelibrary.wiley.com/toc/19412444/2020/44/S1.
Register now for the free 2-part educational series offered by the
American Society for Parenteral and Enteral Nutrition (ASPEN)
specifically on this topic: "Expert Consensus on Omega-3 Fatty Acids
in Parenteral Nutrition: Focus on Critical Care and Major Surgery"
on April 22, 2020, and "Expert Consensus on Omega-3 Fatty Acids in
Parenteral Nutrition: Continuum of Care - From Hospital to Home
Care" on July 9, 2020. Visit the ASPEN Clinical Nutrition Webinar
Series at http://www.nutritioncare.org/webinars/.
* EPA=eicosapentaenoic acid; DHA=docosahexanoic acid
References
(1.) Martindale R, Berlana D, Boullata J, et al. Lipids in
Parenteral Nutrition: Translating Guidelines into Clinical Practice.
JPEN J Parenter Enteral Nutr. 2020;44(suppl S1):S1-S84. (2.) Pradelli L, Mayer K, Klek S et al. ?-3 Fatty-Acid Enriched
Parenteral Nutrition in Hospitalized Patients: Systematic Review
With Meta-Analysis and Trial Sequential Analysis. JPEN J Parenter
Enteral Nutr. 2020;44(1):44-57. (3.) McClave SA, Taylor BE, Martindale RG et al. Guidelines for the
Provision and Assessment of Nutrition Support Therapy in the Adult
Critically Ill Patient: Society of Critical Care Medicine (SCCM) and
American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.).
JPEN J Parenter Enteral Nutr. 2016;40(2):159-211. (4.) Singer P, Blaser AR, Berger MM et al. ESPEN guideline on
clinical nutrition in the intensive care unit. Clin Nutr.
2019;38(1):48-79. (5.) Lapillonne A, Fidler Mis N, Goulet O et al.
ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral
nutrition: Lipids. Clin Nutr. 2018;37(6 Pt B):2324-36.
# # #
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes in
lifesaving medicines and technologies for infusion, transfusion and
clinical nutrition. The company's products and services are used to
help care for critically and chronically ill patients. Fresenius
Kabi's product portfolio comprises a comprehensive range of I.V.
generic drugs, infusion therapies and clinical nutrition products as
well as the devices for administering these products. In the field
of biosimilars, we focus on autoimmune diseases and oncology. In
2019, the first biosimilar product by Fresenius Kabi was launched.
Within transfusion medicine and cell therapies, Fresenius Kabi
offers products for collection and processing of blood and cell
components.
With its corporate philosophy of "caring for life", the company is
committed to putting essential medicines and technologies in the
hands of people who help patients and finding the best answers to
the challenges they face. For more information, please visit fresenius-kabi.com.
For press inquiries, please contact: Nina Espiritu Edelman GmbH Barmbeker Str 4, 22303 Hamburg, Germany T: +49 (0)69 401254-345 nina.espiritu@edelman.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|